Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 9/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.42 |
| ▸ | HTR1F | P30939 | 2/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.37 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17697817 | 0.97 | IL2 (0.46) | IL2GPR55MAP3K5HTR1FCYP11B1 | |
| SCHEMBL16362102 | 0.89 | IL2 (0.48) | IL2GPR55MAP3K5HTR1FBRD4 | |
| SCHEMBL16361893 | 0.89 | IL2 (0.47) | IL2MAP3K5CRACR2A | |
| SCHEMBL16362103 | 0.87 | IL2 (0.48) | IL2GPR55MAP3K5CYP11B1CYP11B2 | |
| SCHEMBL17697813 | 0.87 | IL2 (0.54) | IL2GPR55MAP3K5CYP11B1CYP11B2 | |
| SCHEMBL17697811 | 0.86 | IL2 (0.48) | IL2GPR55MAP3K5HTR1FCRACR2A | |
| SCHEMBL16362064 | 0.85 | IL2 (0.48) | IL2GPR55MAP3K5CYP11B1CYP11B2 | |
| SCHEMBL17697816 | 0.85 | IL2 (0.47) | IL2MAP3K5CRACR2A | |
| SCHEMBL16362100 | 0.83 | IL2 (0.44) | IL2GPR55HTR1FCYP11B1CYP11B2 | |
| SCHEMBL17697815 | 0.82 | CRACR2A (0.47) | IL2MAP3K5GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | claimed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | claimed |
| EP-3010586-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | Lupin Limited (IN) | 2016-04-27 | — | — | EP | claimed |
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
| WO-2014203217-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2014-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | RYR2, NR2C2, CACNA1E | IL2 2831/4885GPR55 385/4885MAP3K5 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.